Skip to content
Search

Latest Stories

Sigma Conference 2020: NPA commissions study to show impact of frozen funding on pharmacy’s ability to deliver for NHS

The National Pharmacy Association (NPA) has commissioned global consultancy firm Ernst & Young to conduct an economic impact assessment of the community pharmacy funding and policy framework in England.

EY’s expert team will assess the robustness of the pharmacy market and consider how far restricted funding and the broader economic environment may impact on efforts to achieve NHS objectives.


The team will conduct literature searches, interviews with stakeholders and a comprehensive survey of NPA members that highlight current pressure points and the impact of foreseeable changes in funding and costs.

EY will also explore what all this means for GPs, hospitals patients and wider society.

Speaking at the Sigma Pharmaceutical conference on Tuesday, the NPA’s Acting Chairman, Andrew Lane, said: “It’s the NPA’s duty, as the voice of independent community pharmacy, to speak out passionately but also factually. Therefore, we have secured the expert services of EY to deliver a detailed financial and operational analysis of the current and future position for independent pharmacies.”

The Association expects to receive telling evidence about the capacity of the pharmacy sector to deliver on NHS objectives, in the context of current flat funding.

“Ministers and NHS officials say they want community pharmacies to be the first port of call for common illnesses, to help people stay well, to take on more clinical services and to relieve pressure on other parts of the system. This can only be achieved on a sustainable basis if resources match the level of ambition. Therefore, we hope they will welcome this economic study as a serious contribution to the evidence base that underpins the development of health & social care policy,” Lane said.

The Pharmaceutical Services Negotiating Committee (PSNC) offered all possible support for the initiative.

PSNC Chief Executive Simon Dukes commented: “This is a really useful initiative from the NPA. We will be supporting the review team in whatever ways we can, and their final report will provide a useful evidence base for us to use in the CPCF annual review process. We expected those discussions with the government to be very much focused on contractors’ costs and capacity this year.”

The final report is expected to be ready by June so that it can be made available to PSNC, the NHS and the Department of Health and Social Care (DHSC) when they undertake the first annual review of funding under the five-year contractual settlement.

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less